(Q88008831)
Statements
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension (English)
Lawrence A Leiter
William T Cefalu
Tjerk W A de Bruin
Ingrid Gause-Nilsson
Jennifer Sugg